View Older Stories

Jun 9, 2026 02:48PM Barclays Downgrades Nuvalent (NUVL) to Equalweight

Jun 9, 2026 12:23PM Baird Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 10:37AM JPMorgan Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 10:19AM Stifel Downgrades Nuvalent (NUVL) to Hold

Jun 9, 2026 09:09AM H.C. Wainwright Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 09:06AM Wells Fargo Downgrades Nuvalent (NUVL) to Equal Weight

Jun 9, 2026 09:05AM Raymond James Downgrades Nuvalent (NUVL) to Market Perform

Jun 9, 2026 08:21AM Wedbush Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 08:06AM Piper Sandler Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 08:06AM Cantor Fitzgerald Downgrades Nuvalent (NUVL) to Neutral

Jun 9, 2026 05:17AM Nuvalent Inc (NUVL) option implied volatility into share price trading up before the bell

Jun 8, 2026 09:06PM GSK (GSK) In Talks To Buy Biotech Nuvalent For More Than $9 bln- FT

Jun 4, 2026 04:10AM Nuvalent (NUVL) PT Lowered to $172 at Bernstein SocGen Group

Jun 3, 2026 06:19AM Leerink Reiterates Outperform Rating on Nuvalent (NUVL)

Jun 2, 2026 07:26AM Nuvalent (NUVL) Reiterated at Overweight by Cantor Fitzgerald

Jun 1, 2026 07:35AM Nuvalent (NUVL) Reiterated at Buy by Stifel on Ph1/2 ALKOVE-1 study Data

May 27, 2026 06:30AM Nuvalent receives FDA priority review for cancer drug neladalkib

May 21, 2026 05:36PM Nuvalent to present cancer drug trial data at ASCO meeting

May 21, 2026 04:36PM Bernstein SocGen Group Starts Nuvalent (NUVL) at Outperform, Top Pick

May 7, 2026 06:36AM Nuvalent, Inc. (NUVL) Misses Q1 EPS by 4c

Apr 30, 2026 08:06AM Guardant Health partners with Nuvalent for cancer diagnostics development

Apr 21, 2026 03:08PM Stifel: 'We believe these AACR datasets flex NUVL's medicinal chemistry prowess'

Apr 21, 2026 06:36AM H.C. Wainwright Reiterates Buy Rating on Nuvalent (NUVL)

Apr 13, 2026 05:52AM Bernstein on US Pharma and Biotech: Who might buy whom?

Apr 7, 2026 06:32AM Nuvalent submits FDA application for lung cancer drug neladalkib

Mar 31, 2026 07:34AM Nuvalent (NUVL) Reiterated at Buy by Stifel After Meet with CEO, CFO

Mar 30, 2026 08:08AM Wells Fargo Starts Nuvalent (NUVL) at Overweight

Feb 26, 2026 07:03AM Nuvalent, Inc. (NUVL) Misses Q4 EPS by 10c

Feb 26, 2026 06:31AM Nuvalent reports Q4 2025 results, awaits FDA decision on zidesamtinib

Jan 12, 2026 06:30AM Nuvalent receives FDA acceptance for cancer drug application

Dec 22, 2025 07:52AM Nuvalent Inc (NUVL) files mixed shelf

Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note

Dec 17, 2025 09:23AM UBS Reiterates Buy Rating on Nuvalent (NUVL)

Nov 24, 2025 07:33AM Truist Securities Starts Nuvalent (NUVL) at Buy

Nov 20, 2025 04:02AM Nuvalent (NUVL) PT Raised to $164 at Jefferies

Nov 19, 2025 04:20PM FDA accepts Nuvalent drug application for lung cancer treatment

Nov 18, 2025 06:50AM Nuvalent (NUVL) PT Raised to $155 at H.C. Wainwright

Nov 18, 2025 06:29AM Nuvalent (NUVL) PT Raised to $155 at Guggenheim

Nov 18, 2025 04:37AM Nuvalent (NUVL) PT Raised to $135 at Goldman Sachs

Nov 17, 2025 04:37PM Nuvalent Inc (NUVL) reportedly marketing $500M stock sale for one day

Nov 17, 2025 11:44AM Nuvalent (NUVL) PT Raised to $135 at Stifel

Nov 17, 2025 11:38AM Nuvalent (NUVL) PT Raised to $125 at Wedbush

Nov 17, 2025 06:30AM Nuvalent reports trial results for ALK lung cancer drug neladalkib

Nov 14, 2025 04:01PM Nuvalent schedules data release for lung cancer drug trial

Nov 12, 2025 05:05AM Canaccord Genuity Starts Nuvalent (NUVL) at Buy

Nov 4, 2025 05:13PM Nuvalent to present zidesamtinib trial data at lung cancer conference

Oct 31, 2025 06:03AM Nuvalent (NUVL) PT Raised to $132 at UBS

Oct 30, 2025 07:31AM Nuvalent, Inc. (NUVL) Misses Q3 EPS by 34c

Oct 27, 2025 08:31AM Nuvalent (NUVL) PT Raised at Piper Sandler; 'Upcoming ALKOVE-1 Update Underappreciated'

Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'

View Older Stories